8 / 32
CRIZOTINIB AND ROS1
•
PROFILE 1001 study was amended and
enrolled a total of 50 ROS1-rearranged
patients in the ROS1 expansion cohort of this
trial
•
ORR 72%, 66%partial responses.
•
Median time to the first response was 7.9
weeks, similarly to ALK-rearranged subgroup
responsive to crizotinib
•
Durability of the response is the main
difference between ALK- and ROS1-rearranged
subgroups, with longer responses in ROS1
(median DOR: 49.1 vs. 64.5 weeks;
median
PFS: 9.7 vs. 19.2 months, respectively)